BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo.
Adult
Aged
Aged, 80 and over
Apoptosis
B-Lymphocytes
/ metabolism
Case-Control Studies
Cell Proliferation
Cohort Studies
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
/ metabolism
Male
Middle Aged
Phosphorylation
Receptors, Antigen, B-Cell
/ metabolism
STAT6 Transcription Factor
/ metabolism
Syk Kinase
/ metabolism
Tumor Cells, Cultured
ZAP-70 Protein-Tyrosine Kinase
/ metabolism
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
24 01 2019
24 01 2019
Historique:
received:
30
04
2018
accepted:
21
11
2018
entrez:
26
1
2019
pubmed:
27
1
2019
medline:
14
8
2020
Statut:
epublish
Résumé
A chronic antigenic stimulation is believed to sustain the leukemogenic development of chronic lymphocytic leukemia (CLL) and most of lymphoproliferative malignancies developed from mature B cells. Reproducing a proliferative stimulation ex vivo is critical to decipher the mechanisms of leukemogenesis in these malignancies. However, functional studies of CLL cells remains limited since current ex vivo B cell receptor (BCR) stimulation protocols are not sufficient to induce the proliferation of these cells, pointing out the need of mandatory BCR co-factors in this process. Here, we investigated benefits of several BCR co-stimulatory molecules (IL-2, IL-4, IL-15, IL-21 and CD40 ligand) in multiple culture conditions. Our results demonstrated that BCR engagement (anti-IgM ligation) concomitant to CD40 ligand, IL-4 and IL-21 stimulation allowed CLL cells proliferation ex vivo. In addition, we established a proliferative advantage for ZAP70 positive CLL cells, associated to an increased phosphorylation of ZAP70/SYK and STAT6. Moreover, the use of a tri-dimensional matrix of methylcellulose and the addition of TLR9 agonists further increased this proliferative response. This ex vivo model of BCR stimulation with T-derived cytokines is a relevant and efficient model for functional studies of CLL as well as lymphoproliferative malignancies.
Identifiants
pubmed: 30679590
doi: 10.1038/s41598-018-36853-8
pii: 10.1038/s41598-018-36853-8
pmc: PMC6345919
doi:
Substances chimiques
Receptors, Antigen, B-Cell
0
STAT6 Transcription Factor
0
STAT6 protein, human
0
SYK protein, human
EC 2.7.10.2
Syk Kinase
EC 2.7.10.2
ZAP-70 Protein-Tyrosine Kinase
EC 2.7.10.2
ZAP70 protein, human
EC 2.7.10.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
701Références
Blood. 1999 Sep 15;94(6):1840-7
pubmed: 10477712
Blood. 2000 Feb 1;95(3):999-1006
pubmed: 10648415
Blood. 2000 Feb 15;95(4):1199-206
pubmed: 10666191
Int Immunol. 2000 Apr;12(4):517-26
pubmed: 10744653
N Engl J Med. 2000 Dec 28;343(26):1910-6
pubmed: 11136261
Blood. 2003 Feb 1;101(3):1087-93
pubmed: 12393552
Blood. 1992 Dec 15;80(12):3173-81
pubmed: 1281692
Br J Haematol. 2003 Nov;123(3):380-8
pubmed: 14616995
Leukemia. 2003 Dec;17(12):2257-317
pubmed: 14671650
Nat Immunol. 2004 Mar;5(3):317-27
pubmed: 14758357
J Exp Med. 2004 Aug 16;200(4):519-25
pubmed: 15314077
N Engl J Med. 2004 Aug 26;351(9):893-901
pubmed: 15329427
Blood. 2005 Mar 1;105(5):2036-41
pubmed: 15514014
Br J Haematol. 2004 Nov;127(4):404-15
pubmed: 15521917
Blood. 2005 Jun 15;105(12):4820-7
pubmed: 15728130
N Engl J Med. 2005 Feb 24;352(8):804-15
pubmed: 15728813
Blood. 2006 May 1;107(9):3708-15
pubmed: 16391014
Cancer Res. 2006 Jul 15;66(14):7158-66
pubmed: 16849562
Cytometry B Clin Cytom. 2006 Jul 15;70(4):309-14
pubmed: 16906588
Blood. 2007 Jan 1;109(1):259-70
pubmed: 16985177
Blood. 2007 Mar 1;109(5):2032-9
pubmed: 17038529
Blood. 2007 Feb 15;109(4):1660-8
pubmed: 17038534
Blood. 2007 May 1;109(9):3989-97
pubmed: 17234734
Blood. 2008 Jan 15;111(2):517-24
pubmed: 17938255
Blood. 2008 Mar 1;111(5):2685-92
pubmed: 18048647
Blood. 2008 May 15;111(10):5173-81
pubmed: 18326821
Leukemia. 2009 Nov;23(11):2118-28
pubmed: 19657365
Blood. 2009 Sep 17;114(12):2560-1; author reply 2561-2
pubmed: 19762501
Immunol Rev. 2010 Sep;237(1):226-48
pubmed: 20727039
Blood. 2011 Jan 13;117(2):563-74
pubmed: 20940416
Blood. 2011 May 19;117(20):5463-72
pubmed: 21385850
Blood. 2011 Jul 28;118(4):e1-15
pubmed: 21602524
Nature. 2011 Jun 05;475(7354):101-5
pubmed: 21642962
Br J Haematol. 2012 Sep;158(5):589-99
pubmed: 22712573
Nature. 2012 Sep 13;489(7415):309-12
pubmed: 22885698
Br J Haematol. 2013 Mar;160(5):711-4
pubmed: 23205585
Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):459-64
pubmed: 23267079
J Exp Med. 2013 Jan 14;210(1):59-70
pubmed: 23296468
Cancer Cell. 2013 Jan 14;23(1):77-92
pubmed: 23328482
Br J Haematol. 2013 Aug;162(3):360-70
pubmed: 23710828
Cell Rep. 2013 Aug 15;4(3):566-77
pubmed: 23933259
Blood. 2013 Oct 24;122(17):3010-9
pubmed: 24014238
Nat Rev Drug Discov. 2014 May;13(5):379-95
pubmed: 24751819
Blood. 2016 Jan 28;127(4):436-48
pubmed: 26508782
Nat Rev Cancer. 2016 Mar;16(3):145-62
pubmed: 26911189
Blood. 2016 Jun 16;127(24):3015-25
pubmed: 27002119
Cytokine Growth Factor Rev. 2016 Dec;32:3-15
pubmed: 27165851
Leukemia. 2017 Dec;31(12):2601-2607
pubmed: 28462919
Exp Hematol. 1997 Apr;25(4):329-37
pubmed: 9131008
Blood. 1998 Apr 1;91(7):2387-96
pubmed: 9516138
J Clin Invest. 1998 Oct 15;102(8):1515-25
pubmed: 9788964